BiotechTube
92Bio

92Bio

Cambridge, United States· Est.
92biotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $255M

Overview

92Bio is a private, preclinical-stage biotech focused on developing best-in-class multispecific T-cell engagers for oncology. Its lead program, NTB-928 (FRα x CD3), is slated for clinical entry in H1 2026, with a γδ T-cell engager for AML following in 2027. The company is backed by experienced venture capital investors and is headquartered in Hayward, California, with a culture emphasizing innovation, collaboration, and calculated risk-taking.

Oncology

Technology Platform

Platform for designing multispecific T-cell engagers (TCEs), with a focus on novel engagers targeting gamma delta (γδ) T-cells in addition to conventional alpha beta T-cells.

Funding History

2
Total raised:$255M
Series B$150M
Series A$105M

Opportunities

The company is pioneering γδ T-cell engagers, a novel modality that could offer advantages in safety and efficacy over conventional TCEs, particularly in immunosuppressive tumor microenvironments.
Successful clinical entry of its lead FRα program in 2026 would provide key validation and position it in the large, high-need ovarian cancer market.

Risk Factors

As a preclinical company, 92Bio faces high technical risk that its novel biologics, especially the γδ T-cell engagers, will translate safely and effectively to humans.
It also operates in the intensely competitive and capital-intensive bispecific antibody space, with dependence on venture financing to reach clinical milestones.

Competitive Landscape

92Bio competes in the crowded T-cell engager field against large biopharma (e.g., Amgen, Roche, Pfizer) and numerous biotechs. Its differentiation lies in its focus on γδ T-cells and fit-for-purpose design, but it must demonstrate clear advantages over established CD3-based approaches and other novel immune cell engagers in development.

More companies in Biologics / Biosimilars →More companies in United States →